Impax Laboratories (IPXL) has an average broker rating of 2.75, which is interpreted as a Hold, as rated by 8 equity analysts. Nonetheless, 1 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 7 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.
Impax Laboratories (IPXL) : The consensus price target for Impax Laboratories (IPXL) is $34.63 for the short term with a standard deviation of $5.32. The most optimist securities analyst among the 8 who monitor the stock believes that the stock can reach $40, however, the pessimist price target for the company is $25.
Company shares have received an average consensus rating of Hold for the current week Impax Laboratories (NASDAQ:IPXL): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $21.99 and $21.53 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $22.39. The buying momentum continued till the end and the stock did not give up its gains. It closed at $22.06, notching a gain of 0.36% for the day. The total traded volume was 1,392,582 . The stock had closed at $21.98 on the previous day.
In a related news,The officer (President, Impax Pharm.) of Impax Laboratories Inc, Nestor Michael sold 5,000 shares at $43.56 on September 10, 2015. The Insider selling transaction had a total value worth of $217,800. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. The Company operates in two segments: Impax Generics and Impax Specialty Pharma. The Impax Generics is focused on the development, manufacture, sale and distribution of the Companys generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma is engaged in the development of brand pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Impax Specialty Pharma is also engaged in the sale and distribution of Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.